Sugi Predict

Sugi Predict / Compounds / SCHEMBL7513

SCHEMBL7513

SCHEMBL7513

C[C@@]12C(=CC(=O)C=C1OP(=O)(O)O)CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 10/20 0.64
▸ NR3C1 P04150 8/20 0.64
▸ HSD17B10 Q99714 6/20 0.64
▸ PGR P06401 5/20 0.64
▸ CYP3A4 P08684 5/20 0.64
▸ CYP2C19 P33261 3/20 0.64
▸ SERPINA6 P08185 3/20 0.64
▸ NR3C2 P08235 2/20 0.64
▸ AR P10275 2/20 0.64
▸ ABCB11 O95342 2/20 0.64
▸ TNF P01375 1/20 0.64
▸ IL6 P05231 1/20 0.64
▸ GLUL P15104 1/20 0.64
▸ ADAM17 P78536 1/20 0.64
▸ GPBAR1 Q8TDU6 1/20 0.64
▸ KMT2A Q03164 2/20 0.60
▸ SHBG P04278 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ NFKB1 P19838 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23565 0.99 HIF1A (0.63) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL28303115 0.99 HIF1A (0.63) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL16094486 0.94 HIF1A (0.61) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL23828321 0.93 HIF1A (0.61) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL28388269 0.93 HIF1A (0.61) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL1930094 0.92 HIF1A (0.63) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL28874596 0.92 HIF1A (0.61) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL28596717 0.92 HIF1A (0.55) HIF1ANR3C1HSD17B10PGRCYP3A4
Phosphoric Acid SCHEMBL27656886 0.89 HIF1A (0.61) HIF1ANR3C1HSD17B10PGRCYP3A4
SCHEMBL4751188 0.89 HIF1A (0.59) HIF1ANR3C1HSD17B10PGRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 860 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255826-A1 PROCESS FOR THE PREPARATION OF ERYTHROCYTES LOADED WITH ONE OR MORE SUBSTANCES OF PHARMACEUTICAL INTEREST AND SO OBTAINED ERYTHROCYTES QUINCE THERAPEUTICS, INC. 2025-08-14 — — US claimed
US-20250144021-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2025-05-08 — — US claimed
US-20250025426-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2025-01-23 — — US claimed
EP-4444275-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2024-10-16 — — EP claimed
EP-4338803-A2 PROCESS FOR THE PREPARATION OF ERYTHROCYTES LOADED WITH ONE OR MORE SUBSTANCES OF PHARMACEUTICAL INTEREST AND SO OBTAINED ERYTHROCYTES EryDel S.p.A. (IT) 2024-03-20 — — EP claimed
WO-2023104380-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2023-06-15 — — WO claimed
EP-2994117-B1 PROCESS FOR THE PREPARATION OF ERYTHROCYTES LOADED WITH ONE OR MORE SUBSTANCES OF PHARMACEUTICAL INTEREST AND SO OBTAINED ERYTHROCYTES Erydel Spa (IT) 2023-06-07 — — EP claimed
EP-4190312-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES Karlsruher Institut für Technologie (DE) 2023-06-07 — — EP claimed
US-20230158041-A1 METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-05-25 — — US claimed
US-20220175955-A1 PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE DANMARKS TEKNISKE UNIVERSITET (DK) 2022-06-09 — — US claimed
EP-0521074-B1 DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE ALZA CORP (US) 1994-03-02 — — EP claimed
US-5178866-A DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE ALZA CORPORATION (US) 1993-01-12 — — US claimed
EP-0521074-A1 DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE. ALZA CORP (US) 1993-01-07 — — EP claimed
WO-1991014426-A1 DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE ALZA CORPORATION (US) 1991-10-03 — — WO claimed
US-4904474-A Delivery of drug to colon by oral disage form ALZA CORPORATION (US) 1990-02-27 — — US claimed
US-4478818-A Ocular preparation housing steroid in two different therapeutic forms ALZA CORPORATION (US) 1984-10-23 — — US claimed
US-4406883-A SHAPES MERRELL DOW PHARMACEUTICALS INC. (US) 1983-09-27 — — US claimed
US-4292300-A METHYL CELLULOSE, WATER, DRUG INVERESK RESEARCH INTERNATIONAL (GB) 1981-09-29 — — US claimed
US-4265875-A HYDROXYPROPYL METHYL CELLULOSE INVERESK RESEARCH INTERNATIONAL (GB) 1981-05-05 — — US claimed
US-4107288-A CROSSLINKED MATRIX OF NATURAL POLYMERS, ALDEHYDE HARDENING AGENT, SOLVATING PHARMACEUTICAL SOCIETY OF VICTORIA (AU) 1978-08-15 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144021-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TREH, GALE, SLC2A8 HIF1A 2738/4885NR3C1 2375/4885HSD17B10 3509/4885
US-20230158041-A1 METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ABCC3, HTR3A, PKD1 HIF1A 1723/4885NR3C1 4539/4885HSD17B10 706/4885
US-20220175955-A1 PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE CD74, MICA, TAP1 HIF1A 3241/4885NR3C1 3679/4885HSD17B10 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.